Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Court of Appeals Upholds Gilenya Compound Patent, Dealing A Blow To Ezra Ventures

Executive Summary

Upholding the validity of Novartis’ Gilenya compound patent, a US Court of Appeals ensures that US-based Ezra’s generic fingolimod hydrochloride product will stay off the market until at least 2019. Generics players challenging the blockbuster multiple-sclerosis brand's patents have had mixed fortunes thus far.


Related Content

Sandoz Sets Forth On Quest To Raise Its Margins
Carry On Cosentyx As Novartis Lines Up More Blockbusters


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts